Norbert Bräu

Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.

Side effects of therapy of hepatitis C and their management

Infective Endocarditis

Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection

Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis

Cancer statistics, 2018

Treatment predictors of a sustained virologic response in hepatitis B and C

Hepatic stellate cells as key target in liver fibrosis

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study1 1The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Bräu, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor College of Medicine, Houston, Texas; Greg Everson, M.D., University of Colorado Health Sciences Center, Denver, Colorado; Michael Fried, M.D., University of North Carolina, Chapel Hill, North Carolina; Robert Gish, M.D., California Pacific Medical Center, San Francisco, California; Ira Jacobson, M.D., Weill Medical College of Cornell University, New York, New York; John W. King, LSU Health Sciences Center, Shreveport, LA; Raymond Koff, M.D., University of Massachusetts Memorial Health Care, Worcester, Massachusetts; William Lee, M.D., University of Texas Southwestern Medical Center, Dallas, Texas; Mark A. Levstik, M.D., The University of Tennessee, Memphis, Tennessee; John G. McHutchison, M.D., Scripps Clinic, La Jolla, California; Marion Peters, M.D., University of California San Francisco, San Francisco, California; Kenneth Sherman, M.D., Ph.D., University of Cincinnati College of Medicine, Cincinnati, Ohio; Coleman Smith, M.D., Minnesota Clinical Research Center, St. Paul, MN; Ronald Wasserman, M.D., Hepatitis Resource Center, Walnut Creek, California.

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis

Multi-input chemical control of protein dimerization for programming graded cellular responses

Coinfection With HIV-1 and HCV—A One-Two Punch

Management of Hepatic Complications in HIV‐Infected Persons

Hepatitis C Virus in the HIV-Infected Patient

Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses

Hepatitis C Infection

Sex differences in immune responses to infectious diseases

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B -unfavorable genotype patients: Impaired viral kinetics and therapeutic response

ISSUES IN SURGICAL TREATMENT OF ENDOCARDITIS INCLUDING INTRAOPERATIVE AND POSTOPERATIVE MANAGEMENT

A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease

Hepatocellular carcinoma

A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors

Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy

Epoetin Alfa Improves Quality of Life in Anemic Hcv–Infected Patients Receiving Combination Therapy

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha†

Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis

Diagnosis, management, and treatment of hepatitis C: An update # † ‡

The changing epidemiology of hepatitis C virus infection in Europe

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection

Direct-acting antiviral agents for HCV infection affecting people who inject drugs

Treating viral hepatitis C: efficacy, side effects, and complications

Interferon Lambda Alleles Predict Innate Antiviral Immune Responses and Hepatitis C Virus Permissiveness

Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C

Hepatitis C virus infection

CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals

Mechanisms of Hepatic Fibrogenesis

Treating hepatitis C

Management of hepatitis C

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients

American Gastroenterological Association Technical Review on the Management of Hepatitis C

Long-term results after cardiac surgery in patients infected with the human immunodeficiency virus type-1 (HIV-1)

Expert opinion on the treatment of patients with chronic hepatitis C

Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Ribavirin - current status of a broad spectrum antiviral agent

Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults

Hepatitis C Virus Entry

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Sex differences in immune responses

Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans

Antiretroviral Treatment of Adult HIV Infection

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

The way forward in HCV treatment — finding the right path

Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Replication of hepatitis C virus

Click Chemistry for Drug Development and Diverse Chemical–Biology Applications

Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses

Flying Under the Radar: The Immunobiology of Hepatitis C

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Azole-Based Energetic Salts

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study

Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization

Treatment of Hepatitis C

Protease inhibitor therapy for hepatitis C virus-infection

Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells

ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary

A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1

Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus

Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype

EASL Recommendations on Treatment of Hepatitis C 2018

Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America

mice: Multivariate Imputation by Chained Equations inR

Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents

Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG

Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions

Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity

Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells

Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants

Pharmacological significance of triazole scaffold

Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

Chronic Hepatitis C in Latinos: Natural History, Treatment Eligibility, Acceptance, and Outcomes

Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients in the Era of Pegylated Interferon and Ribavirin

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse

Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders

Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C

Progression to Cirrhosis in Latinos With Chronic Hepatitis C: Differences in Puerto Ricans With and Without Human Immunodeficiency Virus Coinfection and Along Gender

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy

Zidovudine use but not weight‐based ribavirin dosing impacts anaemia during HCV treatment in HIV‐infected persons

Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients

Cardiac valve replacement in patients infected with the human immunodeficiency virus

Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York city metropolitan area1

Review article: adherence to medication for chronic hepatitis C – building on the model of human immunodeficiency virus antiretroviral adherence research

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa

Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 and chronic kidney disease: an integrated analysis

Once-weekly recombinant human erythropoetin (Epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV)-infected patients receiving interferon-α-2b (IFN)/RBV combination therapy

Update on chronic hepatitis C in HIV/HCV-coinfected patients

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study

FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: Final results

Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial